Astria Therapeutics (NASDAQ:ATXS) Stock Price Down 4.1% - Should You Sell?

Shares of Astria Therapeutics, Inc. (NASDAQ:ATXS - Get Free Report) were down 4.1% during trading on Monday . The stock traded as low as $11.14 and last traded at $11.14. Approximately 60,917 shares traded hands during mid-day trading, a decline of 91% from the average daily volume of 662,459 shares. The stock had previously closed at $11.62.

Analyst Ratings Changes

Several analysts have recently commented on ATXS shares. Evercore ISI raised shares of Astria Therapeutics to a "strong-buy" rating in a report on Wednesday, August 14th. Wedbush reiterated an "outperform" rating and set a $22.00 price target on shares of Astria Therapeutics in a research report on Tuesday, August 13th. TD Cowen started coverage on shares of Astria Therapeutics in a research note on Monday, July 29th. They issued a "buy" rating and a $35.00 price target for the company. Oppenheimer boosted their price objective on shares of Astria Therapeutics from $25.00 to $26.00 and gave the stock an "outperform" rating in a research report on Tuesday, August 13th. Finally, HC Wainwright restated a "buy" rating and set a $16.00 price objective on shares of Astria Therapeutics in a research report on Friday, September 27th. Five analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus target price of $25.20.

Astria Therapeutics Price Performance

The company has a market cap of $607.89 million, a price-to-earnings ratio of -5.01 and a beta of 0.71. The company's 50-day simple moving average is $11.29 and its 200-day simple moving average is $10.54.

Astria Therapeutics (NASDAQ:ATXS - Get Free Report) last released its earnings results on Monday, August 12th. The biotechnology company reported ($0.43) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.05). Equities analysts predict that Astria Therapeutics, Inc. will post -1.72 EPS for the current fiscal year.

Hedge Funds Weigh In On Astria Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the business. RA Capital Management L.P. acquired a new stake in Astria Therapeutics during the first quarter worth about $62,115,000. Vanguard Group Inc. lifted its holdings in Astria Therapeutics by 23.4% in the first quarter. Vanguard Group Inc. now owns 2,535,891 shares of the biotechnology company's stock worth $35,693,000 after acquiring an additional 480,184 shares during the last quarter. Millennium Management LLC lifted its holdings in Astria Therapeutics by 13.5% in the second quarter. Millennium Management LLC now owns 1,842,063 shares of the biotechnology company's stock worth $16,763,000 after acquiring an additional 218,518 shares during the last quarter. Affinity Asset Advisors LLC lifted its holdings in Astria Therapeutics by 15.4% in the second quarter. Affinity Asset Advisors LLC now owns 975,606 shares of the biotechnology company's stock worth $8,878,000 after acquiring an additional 130,000 shares during the last quarter. Finally, Artal Group S.A. bought a new position in Astria Therapeutics in the first quarter worth about $12,445,000. Institutional investors and hedge funds own 98.98% of the company's stock.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.